Mood Stabilizers and Antipsychotics for Acute Mania: A Systematic Review and Meta-Analysis of Combination/Augmentation Therapy Versus Monotherapy
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background Pharmacotherapy remains the mainstay of treatment for acute bipolar mania, but there are many choices, including mood stabilizers (MSs) and antipsychotics (APs). Objective To provide an up-to-date and comprehensive review of the efficacy, acceptability and adverse effects of MSs and APs as combination or augmentation therapy versus monotherapy with either drug class for the treatment of acute mania. Data sources The Cochrane Central Register of Controlled Trials, MEDLINE, PsycINFO, Scopus, and clinical trial databases were searched for articles published between the inception of the databases and July 1, 2014. The following keywords were used: [bipolar disorder, mania, manic, mixed bipolar, schizoaffective] combined with the names of MSs and APs. The reference lists of all the identified randomized controlled trials (RCTs), articles that cited the identified trials, and recent systematic reviews were also checked. Study selection Double-blind RCTs comparing MS and AP as combination or augmentation therapy with either monotherapy during the acute phase treatment of mania were included in the present study. The electronic search yielded 6,445 potential articles in September 2013 and 264 new references in an updated search performed in July 2014. Finally, 19 RCTs were considered eligible for our meta-analyses: MS plus AP combination or augmentation therapy was compared with MS monotherapy in 14 trials (n = 3,651) and with AP monotherapy in 6 trials (n = 606) [one stud…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combination therapy with the atypical antipsychotics quetiapine (level 1), aripiprazole (level 2), risperidone (level 1), or asenapine (level 2) and lithium or divalproex is also recommended as first‐line treatment options with greater efficacy than monotherapy with lithium or divalproex alone, especially in those with higher index severity.144”
In the citing paper
“Trials with paliperidone (level 2 negative) and ziprasidone (level 2 negative) adjunctive therapy to lithium or divalproex showed lack of efficacy.144”
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 2×
“We employed the random-effects model for the metaanalyses [12] because we had anticipated a priori some clinical heterogeneity among the populations and interventions that would be included in this study.”
MethodCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Yatham, L., & Malhi, G. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,506
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399 · cited 1×
“1 Introduction Bipolar disorder, the eighteenth leading cause of disability in the world [1], is a chronic disorder with an estimated lifetime prevalence of around 1 % [2].”
BackgroundGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L. M., Goodwin, G. M., & Geddes, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60873-8 · Cited by 631 · cited 1×
“Furthermore, a recent multiple-treatments meta-analysis of monotherapy for mania [40] showed that there were no significant differences among these MSs for efficacy or acceptability.”
BackgroundTohen, M., Chengappa, K. N. R., Suppes, T., Zarate, C. A., Calabrese, J. R., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Baker, R. W., Risser, R. C., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.1.62 · Cited by 463
Goodwin, G., & Consensus Group of the British Association for Psychopharmacology (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102919 · Cited by 444
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
“Trials with paliperidone (Level 2 -ve) and ziprasidone (Level 2 -ve) adjunctive therapy to lithium or divalproex showed lack of efficacy (145).”
BackgroundGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
“Most patients included in trials which have compared combination/augmentation therapy versus monotherapy with lithium or valproate had prior treatment with lithium or valproate, whereas most participants in trials com-paring combination/augmentation therapy versus dopamine antagonist as monotherapy had not been on med…”
Fountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
“Meta-analytic studies also suggest that combination treatment is superior to monotherapy at the cost of more frequent adverse events; however, these meta-analyses do not distinguish between add-on and combination studies and populations (Scherk et al., 2007; Smith et al., 2007; Tarr et al., 2011; Ogawa et al., 2014).”
Patel, M. X., Sethi, F. N., Barnes, T. R. E., Dix, R., Dratcu, L., Foex, B. A., Garriga, M., Haste, J. C., Kahl, K. G., Lingford-Hughes, A. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118776738 · Cited by 88
Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz064 · Cited by 77
“Meta-analytic studies also suggest that combination treatment is superior to monotherapy at the cost of more frequent adverse events; however, these meta-analyses do not distinguish between add-on studies (which utilize patients resistant to monotherapy) and combination studies (which utilize general patient populatio…”
Malhi, G. S., Gershon, S., & Outhred, T. (2016) · Bipolar Disorders · doi:10.1111/bdi.12455 · Cited by 65
de León, J., & Spina, E. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0881-3 · Cited by 54
Pacchiarotti, I., Anmella, G., Colomer, L., & Vieta, E. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13209 · Cited by 51
Use of antipsychotics and risk of myocardial infarction: a systematic review and meta‐analysis
Yu, Z., Jiang, H., Shao, L., Zhou, Y., Shi, H., & Ruan, B. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12985 · Cited by 39
Vancampfort, D., Probst, M., Daenen, A., Damme, T. V., Binder, M. D., Rosenbaum, S., & Bruyninckx, D. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.05.042 · Cited by 39
Grande, I., & Vieta, E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0235-1 · Cited by 41
“[29] also compared monotherapy with antipsychotics and the combination of antipsychotics with mood stabilizers.”
BackgroundResultKorean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision
Woo, Y. S., Bahk, W.-M., Lee, J. G., Jeong, J.-H., Kim, M.-D., Sohn, I., Shim, S.-H., Jon, D.-I., Seo, J. S., Min, K. J., et al. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.4.434 · Cited by 35
Glue, P., & Herbison, P. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415614109 · Cited by 31
“A recent pair-wise meta-analytic comparison of monotherapy and combination trials identified efficacy advantages for combined AP/MS (Ogawa et al., 2014).”
BackgroundGalling, B., Garcia, M. A., Osuchukwu, U., Hagi, K., & Correll, C. U. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1053457 · Cited by 27
“Expert opinion The efficacy advantages of MS+AP co-treatment for bipolar mania have been well documented [7,17,18].”
BackgroundResultInfluentialKorean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
Jeong, J., Bahk, W., Woo, Y. S., Lee, J. G., Kim, M.-D., Sohn, I., Shim, S.-H., Jon, D., Seo, J. S., Kim, W. K., et al. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.2.155 · Cited by 25
Cheng, C., Chang, W. H., Lin, Y., Chen, P. S., Yang, Y. K., & Bai, Y. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103480 · Cited by 24
Jeong, J., Bahk, W., Woo, Y. S., Yoon, B.-H., Lee, J. G., Kim, W., Sohn, I., Park, S., Shim, S.-H., Seo, J. S., et al. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2023.21.1.32 · Cited by 21
“of combination therapy over monotherapy in terms of efficacy for mania, a conclusion based on results from clinical trials and meta-analyses [42-47].”
Tajika, A., Hori, H., Iga, J., Koshikawa, Y., Ogata, H., Ogawa, Y., Watanabe, K., Kato, T., Matsuo, K., & Kato, M. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac050 · Cited by 22
“(Ogawa et al., 2014) pointed out that there was no difference in dropout for any reason in both comparisons 1 and 2.”
BackgroundSelf-citationDatta, S., Suryadevara, U., & Cheong, J. (2021) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001051 · Cited by 27
Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary
Woo, Y. S., Bahk, W., Jeong, J., Lee, J. G., Kim, W., Sohn, I., Park, S., Shim, S.-H., Seo, J. S., Choo, I. H., et al. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.4.747 · Cited by 20
“Combination treatment may be more efficacious for manic episodes, but may also be more burdensome than the continuation of MS or AAP monotherapy when either monotherapy has not been successful [23,24].”
BackgroundPsychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study
Kleimann, A., Schrader, V., Stübner, S., Greil, W., Kahl, K. G., Bleich, S., Grohmann, R., Frieling, H., & Toto, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.037 · Cited by 19
Prescribing practices of Indian psychiatrists in the treatment of bipolar disorder
Reddy, Y. C. J., Jhanwar, V., Nagpal, R., Reddy, M., Shah, N., Ghorpade, S., & Kulkarni, S. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419826718 · Cited by 14
Systematic Review of Recent Guidelines for Pharmacological Treatments of Bipolar Disorders in Adults
Hammett, S., & Youssef, N. A. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900409 · Cited by 14
Lieslehto, J., Tiihonen, J., Lähteenvuo, M., Kautzky, A., Akhtar, A., Ármannsdóttir, B., Leucht, S., Correll, C. U., Mittendorfer‐Rutz, E., Tanskanen, A., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103108 · Cited by 10
“28 Thus, the treatment choice should be carefully balanced, ensuring that patients with more severe presentations and a poorer prognosis receive more ef fi ca-cious regimens while those with a better prognosis are spared unnecessary adverse effects.”
Guidelines for the management of psychosis in the context of mood disorders
Bassett, D. L., Boyce, P. M., Lyndon, B., Mulder, R., Parker, G. B., Porter, R., Singh, A., Bell, E., Hamilton, A., Morris, G., et al. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.01.047 · Cited by 11
Flores‐Ramos, M., Leff, P., Fernández‐Guasti, A., & Palars, C. B. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.02.003 · Cited by 10
“stabilizer monotherapy as the initial therapy for acutely manic patients without priormedication (Ogawa et al., 2014).”
Assion, H.-J., Schweppe, A., Reinbold, H., & Frommberger, U. (2018) · Der Nervenarzt · doi:10.1007/s00115-018-0507-3 · Cited by 8
Asenapine for the treatment of bipolar disorder
Marazziti, D., Mucci, F., Falaschi, V., & Dell’Osso, L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1617849 · Cited by 8
“A metanalysis showed that the antimanic effect of lithium or valproate-SGAs combination is superior to that of lithium or valproate monotherapy [9].”
BackgroundInfluentialMahajan, V., Arora, M., Tandon, V., Gillani, Z., & Praharaj, S. K. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001064 · Cited by 8
Ringen, P. A., Reponen, E. J., Vedal, T. S. J., Andreassen, O. A., Steen, N. E., & Melle, I. S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00649 · Cited by 9
“They also effectively reduce the psychotic symptoms of affective psychoses in manic or depressive episodes (3), and some are approved as mood stabilizers in bipolar disorder (4, 5).”
BackgroundMengistu, M. E., Handebo, S., Kassaw, A. T., Dagnew, E. M., Mekonnen, G. A., & Birarra, M. K. (2023) · Annals of General Psychiatry · doi:10.1186/s12991-023-00444-3 · Cited by 9
“The evidence for the effectiveness of old-generation antipsychotics for the treatment of mania is, however, limited and the current guidelines advise restricting their use to short-term therapy to decrease possible side effects [37].”
BackgroundTreatment of Acute Manic Episodes in Bipolar Disorder
Atagün, M. İ., & Oral, T. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27411 · Cited by 17
Jing, P., Su, J., Zheng, C., Mei, X., & Zhang, X. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1057780 · Cited by 8
“For acute BD mania, monotherapy with either mood stabilizers or antipsychotics is recommended, and the combination of a mood stabilizer with an antipsychotic is suggested for cases in which monotherapy is not sufficient (16).”
BackgroundChanging Trends in Treatment of Acute Mania: Experience of a Tertiary Centre Over a Decade
Arıkan, M. K., Poyraz, C. A., Baş, A., Sağlam, N. G. U., Batun, G. Ç., Gültekin, G., & Poyraz, B. Ç. (2015) · Psychiatric Quarterly · doi:10.1007/s11126-015-9388-9 · Cited by 5
“combination/augmentation therapy was associated with more side effects, primarily somnolence [28].”
BackgroundMorana, P., Mucci, F., Baroni, S., Vecchia, A. D., Piccinni, A., Morana, B., & Marazziti, D. (2020) · Clinical Case Reports · doi:10.1002/ccr3.2462 · Cited by 2
Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania
Palacios‐Garrán, R., Llorca-Bofí, V., Arteaga-Henríquez, G., & del Agua, E. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.828088 · Cited by 2
About diagnosis and therapy of bipolar disorder
An, B. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2021121031155 · Cited by 3
Mood Stabilizers: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy
Schoretsanitis, G., & Paulzen, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_39 · Cited by 2
Paun, R., Pavel, A. N., & Matei, V. P. (2020) · Psychiatry and Clinical Psychopharmacology · doi:10.5455/pcp.20200917051316 · Cited by 1
Treatment of Mania with Lithium
Bauer, M., & Gitlin, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31214-9_6 · Cited by 1
Mood Stabilizers: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy
Schoretsanitis, G., & Paulzen, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-56015-1_39-1 · Cited by 1
Tercer Consenso Argentino sobre el manejo de los Trastornos Bipolares. Segunda Parte B
Cetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Herbst, L., Marengo, E., Torrente, F. M., Maresca, T., Bustin, J., Morra, C. A., et al. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i160.459 · Cited by 5
Asenapine in the Treatment of Acute Mania: A Real-World Observational Study With 6 Months Follow-Up
Ostinelli, E. G., Cavallotti, S., Castelnovo, A., Guanella, E., Gambini, O., & D’Agostino, A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000374 · Cited by 1
Rodríguez, A. M., & Etxezarraga, X. P. D. M. (2021) · doi:10.36959/784/427 · Cited by 1
Combination Therapies and Switching of Agents in Depression and Bipolar Disorders
Folsche, T., Maier, H. B., Hillemacher, T., & Frieling, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_437 · Cited by 1
Beyond Lithium: Other Treatments for Bipolar Disorder
Bauer, M., & Gitlin, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31214-9_13
Psychotropic drugs and medication
Scholey, A. B., Parrott, A., & Ogden, E. B. (2019) · Swinburne figshare (Swinburne University of Technology)
Adri, A. A. (2020) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390320916543 · Cited by 1
“The literature search revealed four separate meta-analyses of multiple randomized controlled clinical trials that support the intervention of combination therapy (Geoffroy et al., 2012; Glue & Herbison, 2015; Ogawa et al., 2014; Scherk et al., 2009).”
BackgroundGuidelines on Mood Stabilizers
Gfesser, J., & Kittel‐Schneider, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_117-1
Kloiber, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_46-1
Combination Therapies and Switching of Agents in Depression and Bipolar Disorders
Folsche, T., Maier, H. B., Hillemacher, T., & Frieling, H. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_437-1 · Cited by 1
Rodríguez, A. M., & Etxezarraga, X. P. D. M. (2021) · Current Psychiatry Research and Reviews · doi:10.2174/2666082218666211221090624
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg002
Renes, J., Maijer, K., Hillegers, M. H. J., Schulte, P. F. J., Kupka, R., de Witte, L. D., & Luykx, J. J. (2022) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2801-7_3
Guidelines on Mood Stabilizers
Gfesser, J., & Kittel‐Schneider, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_117
Kloiber, S. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_46
Treatment of delirious mania with catatonia in a community teaching hospital: A case series
Wheeler, T., & Vasan, S. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100190
Comorbidity of Mental and Somatic Pathology in the Study of the Association of Blood Folate Levels
Bataev, K. M., Avduev, I. S., Bataeva, M. K., Chupalaev, A. D., Todasheva, M. A., Bachigov, A. T., Irisbaeva, L. H., & Saralieva, E. S. (2023) · Archives of Pharmacy Practice · doi:10.51847/hncifgekhn
An Update on the Treatment of Manic and Hypomanic States
Jauhar, S., & Wong, S. L. A. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.021
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg002.pub2
Mengistu, M. E., Berassa, S. H., Kassaw, A. T., Dagnew, E. M., Mekonnen, G. A., & Birarra, M. K. (2024) · Figshare · doi:10.6084/m9.figshare.26580794
Bottaro, F. J., Scalera, M., Nosari, G., Venuti, L., Callari, A., Giovanna, G., Pini, C., Brambilla, P., & Delvecchio, G. (2026) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2026.100322
Sarrazin, S. (2020) · theses.fr (ABES) · doi:10.70675/6d080694ze9ecz4314z8187zef612b9bbc65
Prisco, M. D., Oliva, V., Miola, A., Fornaro, M., Dragioti, E., Croatto, G., Carvalho, A. F., Berk, M., Nikolitch, K., Saraf, G., et al. (2026) · BMJ · doi:10.1136/bmj-2026-100216
Metadata
- Authors
- Ogawa, Y., Tajika, A., Takeshima, N., Hayasaka, Y., & Furukawa, T. A.
- Affiliations
- Kyoto University (JP)
- Corresponding author
- Ogawa, Yusuke
- Venue
- CNS Drugs
- Published
- 2014-08-27
- Volume
- 28
- Issue
- 11
- Pages
- 989-1003
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2000154813
- Cited by
- 66
- References
- 37
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 7 · 2022: 9 · 2021: 8 · 2020: 6 · 2019: 8 · 2018: 6 · 2017: 1 · 2016: 8 · 2015: 6
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- International Business Machines Corporation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bipolar mania, mood stabilizers, antipsychotic drugs, combination therapy, augmentation therapy, monotherapy, acute mania treatment, treatment response and remission, adverse events, treatment discontinuation
- MeSH terms
- Acute Disease, Bipolar Disorder, Drug Therapy, Combination, Humans, Antipsychotic Agents, Treatment Outcome, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.